Anesthesia for Electroconvulsive Therapy: A Niche Role for Sevoflurane

Area of Science:

• Anesthesiology
• Neuroscience
• Psychiatry

Background:

• Electroconvulsive therapy (ECT) commonly uses intravenous (IV) anesthetics like methohexital, propofol, or ketamine.
• Sevoflurane, an inhalational anesthetic, has been available for decades but is rarely mentioned in ECT guidelines.
• Existing research on sevoflurane for ECT is limited, necessitating a comprehensive review.

Purpose of the Study:

• To systematically review and meta-analyze randomized clinical trials comparing sevoflurane with IV anesthetics for ECT.
• To evaluate the efficacy and safety of sevoflurane in the context of ECT anesthesia.

Main Methods:

• A systematic review and meta-analysis of 12 randomized clinical trials involving 377 patients.
• Comparison of sevoflurane versus IV anesthetics (barbiturates, ketamine, propofol) in ECT procedures.
• Analysis of EEG seizure duration, postictal suppression, hemodynamic responses, and adverse events.

Main Results:

• Sevoflurane was associated with shorter EEG seizure duration compared to barbiturates, ketamine, and propofol.
• Hemodynamic effects: Sevoflurane increased heart rate and mean arterial pressure more than barbiturates and propofol.
• Overall adverse events did not significantly differ between sevoflurane and IV anesthetics; however, additional equipment and complexity are noted disadvantages.

Conclusions:

• Current evidence does not strongly support the routine use of sevoflurane for ECT anesthesia due to its impact on seizure duration and hemodynamics.
• Potential niche applications exist for patients with needle phobia, agitation, or those experiencing prolonged seizures.
• Sevoflurane may offer benefits in late pregnancy by potentially inhibiting uterine contractions, with adverse effects manageable by adjusting administration timing.